GlassScriptPhysician profile
Sarah J Davis
NPI 1457911810
$6,856.37
in general payments reported to CMS, 2019-2025
37 companies · $2,256 in 2025
The $2,256 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,061 · 2022: $926 · 2023: $404 · 2024: $1,209 · 2025: $2,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,869.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $558.18 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $511.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $491.85 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $477.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $344.42 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $317.63 | 2021-2025 | Verquvo |
| Biogen, INC. | $235.65 | 2021-2022 | |
| Amarin Pharma, INC. | $217.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $213.62 | 2021-2025 | Spravato, Xarelto |
| Radius Health, INC. | $193.50 | 2024-2025 | Tymlos |
| Pfizer INC. | $175.32 | 2021-2025 | |
| Glaxosmithkline, LLC. | $142.47 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $140.89 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.97 | 2021-2024 | Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.